AIxCrypto Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Item 15. Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this Annual Report:
1.Financial Statement Schedules.
All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and accompanying notes included in this Form 10-K.
2.Exhibits.
See exhibits listed below.
(b) Exhibits:
EXHIBIT INDEX
| Exhibit No. | Description | Form | File No. | Exhibit | Filing Date |
|---|---|---|---|---|---|
| 2.1 | Stock Purchase Agreement dated July 20, 2023 with Chembio Diagnostics, Inc., Biosynex, S.A. and Qualigen, Inc. | 8-K | 001-37428 | 2.1 | 7/26/2023 |
| 3.1 | Amended and Restated Certificate of Incorporation of Ritter Pharmaceuticals, Inc. | 8-K | 001-37428 | 3.1 | 7/1/2015 |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation | 8-K | 001-37428 | 3.1 | 9/15/2017 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation | 8-K | 001-37428 | 3.1 | 3/22/2018 |
| 3.4 | Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 29, 2020 | 8-K | 001-37428 | 3.1 | 5/29/2020 |
| 3.5 | Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split] | 8-K | 001-37428 | 3.2 | 5/29/2020 |
| 3.6 | Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020 | 8-K | 001-37428 | 3.3 | 5/29/2020 |
| 3.7 | Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 | 8-K | 001-37428 | 3.4 | 5/29/2020 |
| 3.8 | Amended and Restated Bylaws of the Company, as of August 10, 2021 | 8-K | 001-37428 | 3.1 | 8/13/2021 |
| 3.9 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on November 21, 2022 | 8-K | 001-37428 | 3.1 | 11/22/2022 |
| 3.10 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on October 28, 2024 | 8-K | 001-37428 | 3.1 | 11/01/2024 |
| 3.11 | Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A-3 Preferred Stock, as filed with the Secretary of State of the State of Delaware on July 28, 2025. | 8-K | 001-37428 | 3.1 | 07/28/2025 |
| 3.12 | Certification of Amendment to Certificate of Incorporation, filed with the Delaware Secretary of State on November 14, 2025 | 8-K | 001-37428 | 3.1 | 11/17/2025 |
| 4.1 | Description of Common Stock | 10-K/A | 001-37428 | 4.9 | 7/7/2023 |
| 10.28 | Securities Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt | 8-K | 001-37428 | 10.1 | 12/22/2022 |
| 10.29 | 8% Senior Convertible Debenture Due December 22, 2025 in favor of Alpha Capital Anstalt | 8-K | 001-37428 | 10.2 | 12/22/2022 |
| 10.30 | Registration Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt | 8-K | 001-37428 | 10.3 | 12/22/2022 |
| 10.31+ | Letter to Michael Poirier, dated January 13, 2023, regarding compensatory changes | 10-K | 001-37428 | 10.31 | 5/2/2023 |
| 10.32+ | Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes | 10-K | 001-37428 | 10.32 | 5/2/2023 |
| 10.33+ | Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes | 10-K | 001-37428 | 10.33 | 5/2/2023 |
| 10.34 | Amendment No. 1 with regard to Securities Purchase Agreement dated December 5, 2023 with Alpha Capital Anstalt | 8-K | 001-37428 | 10.1 | 12/7/2023 |
| 10.35 | Amendment and Settlement Agreement dated July 19, 2023 with NanoSynex, Ltd. | 8-K | 001-37428 | 10.1 | 7/26/2023 |
| 10.36+ | Separation Agreement and General Release dated June 20, 2023 with Amy Broidrick | 10-Q | 001-37428 | 10.1 | 8/14/2023 |
| 14.1 | Code of Business Conduct and Ethics | 8-K | 001-37428 | 14.1 | 5/29/2020 |
| 10.11 | Form of Registration Rights Agreement, dated as September 19, 2025, between Qualigen Therapeutics, Inc. and each Subscriber | 8-K | 001-37428 | 10.2 | 10-03/2025 |
| 19.1 | Insider Trading Policy | ||||
| 21.1 | Subsidiaries of the Registrant | ||||
| 23.1* | Consent of HTL International LLC, independent registered public accounting firm | ||||
| 23.2* | Consent of WithumSmith+Brown, PC independent registered public accounting firm | ||||
| 24.1 | Power of Attorney (included on signature page) | ||||
| 31.1 | Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 | Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1 | Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 97.1* | Clawback Policy |
| 101.INS# | Inline XBRL Instance Document. |
| 101.SCH# | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL# | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF# | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB# | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE# | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- Filed or furnished herewith.
** Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC upon request.
***Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
- Indicates management contract or compensatory plan or arrangement.
XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.